Palantir Technologies is trading 3.5% down at €106.72 after the UK’s Office for Statistics Regulation raised concerns regarding effectiveness claims for the NHS Federated Data Platform.
- The regulator stated that NHS England will amend public statements about the platform’s impact following scrutiny of its reported benefits.
- The development puts Palantir’s significant role in UK healthcare analytics under the spotlight, adding company-specific pressure.
- The stock's decline comes as broader technology sector sentiment remains fragile, amplifying the impact of the regulatory news.